IDEXX stock holds after Q2 beat and 2026 guidance
Published on 08/28/2026 at 19:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IDEXX Laboratories (US45168D1046) held a $545.08 close on August 27, 2026, after second-quarter 2026 earnings of $4.27 a share and revenue of $1.22 billion beat expectations.
The fresh quarter also lifted the year's frame: guidance for fiscal 2026 calls for EPS of $14.69 to $14.94, while revenue guidance sits at $4.7 billion.
Q2 numbers still matter
The comparison is clean. Q2 2026 EPS of $4.27 topped the $3.94 consensus by $0.33, and revenue of $1.22 billion exceeded the $1.20 billion estimate.
That kind of beat matters more than a one-day move because it sets the base for the rest of 2026. The market is still judging whether the company can keep margin discipline while growth stays in the high single digits.
Guidance gives the frame
Fiscal 2026 EPS guidance of $14.69 to $14.94 sits above the $14.64 consensus cited in the latest earnings summary. Revenue guidance of $4.7 billion also gives investors a concrete benchmark for the second half.
For a diagnostics name, that combination of $1.22 billion quarterly sales and a $4.7 billion full-year target is more important than a small daily price swing.
Product focus
IDEXX's veterinary diagnostics platform remains the core business, with tests and instruments used across companion animal clinics and other animal-health settings. That mix helps explain why quarterly revenue can move with clinic utilization and installed-base demand.
The share price was $545.08 on August 27, 2026, and MarketBeat's latest earnings page showed a fair market value quote of $544.93 at 1:55 p.m. Eastern on August 28, 2026.
Fact box
Company: IDEXX Laboratories, Inc.
ISIN: US45168D1046
Ticker: IDXX
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $545.08 USD
Market cap: $42.94 billion
Sector / Industry: Health Care / Diagnostics & Research
Index membership: Nasdaq-100
